Purchase this article with an account.
Frank Gambino, hui liu, Cian Walsh, Charles S Bouchard, Ping Bu, Bruce Ira Gaynes, Liang Qiao; Anti-Inflammatory Action of a Novel Tetrapeptide in a Corneal Epithelial Cell Culture Model. Invest. Ophthalmol. Vis. Sci. 2018;59(9):3823.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Dry Eye Disease (DED) is a disorder that affects over ten million worldwide. The pathogenesis of DED is not fully understood, however, inflammation at the ocular surface is a hallmark of the disease and its symptoms. Our purpose is to explore the anti-inflammatory effect of a novel synthetic tetrapeptide on experimental corneal inflammation in a cell culture model.
Human Corneal Epithelial Cells (HCECs) were treated with inflammasome inducers such as LPS, HNE, Nigericin, and others to model an inflammatory DED-state. Using a dosage response model, HCECs were pre-treated with a synthetic tetrapeptide followed by exposure to aforementioned suspected inflammatory DED inducers followed by measurement of IL-6 expression.
Levels of pro-inflammatory cytokine IL-6 in HCECs pre-treated with our synthetic peptide followed by treatment with inflammatory agonists decreased from 52.45 ± 0.9121 pg/mL IL-6 with no pre-treatment of tetrapeptide to 38.08 ± 1.368 pg/mL IL-6 with pre-treatment of tetrapeptide (P<0.05) thereby approaching normative levels.
The novel synthetic tetrapeptide evaluated in this study appears useful in reducing levels of pro-inflammatory cytokines such as IL-6 to normative levels. These results provide a basis for a novel therapeutic drug in treating DED caused by putative inflammatory pathways.
This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.
This PDF is available to Subscribers Only